Niceritrol – an Anti-Hyperlipidemic Agent

Niceritrol – an Anti-Hyperlipidemic Agent

niceritrolUses of Niceritrol

Being a hypolipidemic drug, Niceritrol is used to affect the levels of cholesterol profile. Niceritrol can be used to lower the levels of cholesterol along with LDL (low density lipoprotein) while it increases the levels of HDL (high density lipoprotein) and the levels of healthy cholesterol. The medicine is used to treat patients suffering from imbalanced cholesterol levels, cardiovascular risks and other kidney and liver functions.

The dose of Niceritrol varies from patient to patient and are suggested by the doctor on the basis of evidence-based guideline offered by National Cholesterol Education Program (NCEP) and Adult Treatment Panel III (ATP III) of United States of America.

Niceritrol is an effective medicine to lower triglycerides by a range of 20-50 percent. While Niceritrol increases the levels of High Density Lipoprotein (HDL) while it efficiently decreases the levels of Low Density Lipoprotein (LDL).

LGM Pharma is a US based supplier of the API (Active Pharmaceutical Ingredient) Niceritrol, for research and development purposes.  Niceritrol is a derivative of Niacin which is a hypolipidemic agent. The chemical name of Niceritrol is 3-Pyridinecarboxylic acid, 2,2-bis[[(3-pyridinylcarbonyl)oxy]methyl]-1,3-propanediyl ester, while its chemical formula is C29-H24-N4-O8.

Possible Side Effects of Niceritrol

Niceritrol is a significant and very effective niacin based medicine for reducing the cardiovascular risks and improving the good cholesterol (High Density Lipoprotien) levels. It is also considered as a cure for some of the kidney and liver problems. Yet it may cause some serious side effects in some of the patients. Niceritrol may cause Hyperglycemia and it may also result in liver damage.’

*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service